At the heart of this research lies a specific protein isoform, RUNX1C, which is a variant product of the RUNX1 gene, known to be a critical regulator of normal blood cell differentiation and function. This isoform had been relatively understudied, but the JAX team, led by assistant professor Eric Wang, has uncovered its pivotal role in enabling AML cells to withstand chemotherapy and enter a protective dormant state. The study, published in the prestigious journal Blood Cancer Discovery, underscores a sophisticated regulatory axis involving RUNX1C and a downstream gene, BTG2, which together orchestrate the quiescence and survival of leukemia cells in the face of genotoxic stress from chemotherapeutic agents.

The investigation employed a comprehensive analysis of patient-derived data, examining samples taken before chemotherapy and after AML relapse. Remarkably, the researchers identified a pronounced increase in DNA methylation—a chemical modification that generally suppresses gene expression—in a genomic region controlling RUNX1. This epigenetic switch led to enhanced production of the RUNX1C isoform specifically, rather than a general increase in RUNX1 expression. This precision epigenetic alteration is critical because it activates a cascade of molecular events that skew the leukemia cells toward chemoresistance.

Delving deeper into mechanism, it was revealed that RUNX1C upregulates the BTG2 gene. BTG2 functions as a cell cycle regulator by interfering with RNA activity, effectively dampening cellular proliferation signals. The consequence is a shift in leukemia cells to enter a quiescent or dormant state, wherein they cease dividing and thus evade the cytotoxic effects of chemotherapy, which preferentially targets rapidly dividing cells. This cellular dormancy effectively cloaks the cancer cells from therapeutic elimination, allowing them to persist silently and ultimately rekindle disease when treatment ceases.

Wang emphasizes the clinical implications of these findings, noting the scarcity of effective treatments for AML patients who relapse following standard chemotherapy regimens. This research not only elucidates the molecular underpinnings of relapse but also identifies RUNX1C as a strategically viable target for therapeutic intervention. Importantly, the team demonstrated that experimentally inhibiting RUNX1C in AML cellular models and mouse systems significantly lowered chemoresistance, as cancer cells were forced out of quiescence, becoming once again vulnerable to chemotherapeutic drugs.

Central to this innovative approach is the application of antisense oligonucleotides (ASOs), sophisticated RNA-targeting molecules capable of binding to specific RNA transcripts and blocking protein production. While ASO technology has seen success in rare neurological disorders, its use in AML and other cancers remains largely unexplored. The promising results from Wang’s lab suggest that ASOs engineered specifically to suppress RUNX1C expression could restore chemotherapy sensitivity by preventing leukemia cells from entering dormancy, offering a potent combination strategy alongside conventional treatments.

The functional experiments conducted by Dr. Cuijuan Han, the study’s lead author, further validated the causative role of RUNX1C in chemoresistance. Overexpression of RUNX1C rendered AML cells resistant to multiple chemotherapeutic drugs, while genetic silencing of this isoform sensitized cells, underscoring a direct link between RUNX1C abundance and therapy outcomes. These meticulously executed gain- and loss-of-function studies highlight the isoform-specific nature of chemoresistance mechanisms, an aspect previously overlooked in AML research.

This work also serves as an important proof of concept that RNA isoforms—which arise from alternative processing of the same gene transcript—are not mere biological noise but critical regulators of cancer cell behavior. Such isoform-specific targeting may revolutionize the understanding and treatment of not only AML but potentially a broad spectrum of cancers. Wang notes the potential to extend these insights, proposing future research to explore isoform modulation across different malignancies and therapeutic contexts.

Beyond its immediate translational potential, this research adds a novel layer to the complex understanding of cancer biology. The epigenetic regulation of gene isoforms introduces a nuanced dimension to how leukemic cells adapt to and resist chemotherapeutic pressure. It shifts the paradigm from focusing solely on gene-level expression changes to appreciating the diversity of RNA isoforms driving disease progression. This enhanced comprehension could inform biomarker development and therapeutic design, optimizing individualized treatment strategies.

The Jackson Laboratory team plans to continue refining RNA-targeting technologies to enhance specificity and efficacy in vivo, as well as to investigate combinational therapies pairing ASOs with emerging targeted agents. They envision that the tailored inhibition of RUNX1C could be integrated into multi-modal treatment regimens, improving remission durability and ultimately patient survival. Given the high relapse rate and dismal prognosis for relapsed AML patients, such advancements could markedly shift clinical outcomes.

In conclusion, the JAX study illuminates a transformative avenue in cancer therapeutics by pinpointing an isoform-specific pathway that governs leukemia cell dormancy and chemoresistance. Through the innovative use of RNA-targeting antisense technology, there is newfound hope for overcoming one of the most stubborn hurdles in AML treatment. This research not only enhances fundamental cancer biology knowledge but also foreshadows the arrival of precision molecular interventions capable of disabling the stealth tactics employed by lethal cancers.

Subject of Research: Animals

Article Title: An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance

News Publication Date: 11-Aug-2025

Web References:

• https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-24-0327/764069/An-Isoform-Specific-RUNX1C-BTG2-Axis-Governs-AML
• http://dx.doi.org/10.1158/2643-3230.BCD-24-0327

References:
Wang, E., Han, C., et al. An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance. Blood Cancer Discovery. 11 August 2025.

Image Credits: The Jackson Laboratory

Keywords: Leukemia, Myeloid leukemia, RNA

Acute myeloid leukemia is notorious for its rapid progression and resistance to conventional therapies, often leading to poor clinical outcomes and high mortality rates. At the heart of AML’s malignancy lies a complex network of genetic and epigenetic alterations, among which aberrant activation of oncogenes like MYC is a recurring theme. MYC orchestrates an array of cellular processes essential for cancer cell survival, including metabolism, cell cycle progression, and apoptosis evasion. However, targeting MYC directly has remained an elusive goal due to its “undruggable” nature, leaving scientists to explore upstream regulatory mechanisms that govern its function.

The recent study spearheaded by Zhao, K., Zhang, H., Wang, S., and colleagues breaks new ground by identifying METTL13 as a critical post-transcriptional modulator of MYC in AML cells. METTL13, a member of the methyltransferase family, enzymatically modifies specific substrates through methylation, thereby altering their function and stability. Through an intricate series of in vitro and in vivo experiments, the researchers demonstrated that silencing METTL13 expression led to a marked decrease in MYC levels, which in turn severely compromised leukemia cell viability. This direct link illuminated a previously uncharted regulatory layer influencing MYC activity and AML cell survival.

Delving deeper into molecular details, the study elucidated how METTL13-mediated methylation impacts the translation machinery and protein synthesis within AML cells. METTL13 was found to methylate components involved in the initiation of mRNA translation, thereby enhancing the production of MYC protein. This post-transcriptional control mechanism allows leukemia cells to sustain high MYC protein levels irrespective of changes in MYC mRNA expression, highlighting a sophisticated strategy that leukemia cells exploit to maintain their oncogenic drive. Such insights deepen our understanding of cancer biology, particularly showcasing how epigenetic modifications intersect with gene expression regulation to fuel malignancy.

To validate the clinical relevance of their findings, the researchers analyzed patient-derived AML samples and corroborated that METTL13 expression was significantly elevated compared to healthy controls. This overexpression correlated with higher MYC protein levels, reinforcing the pathophysiological link described in experimental models. Furthermore, patients exhibiting increased METTL13 activity had poorer prognostic indicators, suggesting METTL13 could serve as both a biomarker and a therapeutic target in AML. These correlations underscore the translational potential of targeting METTL13 to disrupt MYC-driven leukemogenesis.

Crucially, functional assays revealed that pharmacological inhibition or genetic knockdown of METTL13 induced apoptosis in AML cell lines without affecting normal hematopoietic cells, hinting at a therapeutic window that could be exploited for selective AML targeting. This specificity offers hope for designing treatments that minimize collateral damage to healthy tissue, a fundamental challenge in current chemotherapy regimens. The study also provided preliminary evidence that combining METTL13 inhibition with existing therapies could potentiate anti-leukemic effects, laying a foundation for combinatorial treatment strategies.

The mechanistic insights uncovered by Zhao and colleagues have broad implications, especially considering the notorious difficulty of directly targeting MYC. By shifting the therapeutic focus upstream to METTL13, researchers are unveiling a novel strategy that could circumvent previous barriers. Moreover, understanding how methyltransferase enzymes modulate oncogene expression opens new investigative pathways in cancer biology, as similar mechanisms may be operative in other malignancies characterized by MYC dysregulation.

From a therapeutic development perspective, the discovery that METTL13 supports leukemia cell survival via MYC regulation ignites enthusiasm for drug discovery efforts aimed at inhibiting this enzyme’s methyltransferase activity. Small-molecule inhibitors targeting METTL13 could represent the next generation of epigenetic therapies, with the potential for high efficacy and reduced systemic toxicity. Nonetheless, challenges remain, including the need to delineate METTL13’s role in normal physiology to avoid unintended side effects, and optimizing inhibitor specificity to prevent off-target interactions.

The study further sheds light on the broader landscape of epitranscriptomics—the diverse chemical modifications that regulate RNA function and protein synthesis. METTL13’s influence on mRNA translation through methylation exemplifies how post-transcriptional modifications profoundly impact cellular behavior and cancer biology. As investigations into the epitranscriptomic code accelerate, enzymes like METTL13 may emerge as central nodes controlling oncogenic programs across cancer types.

Beyond AML, these findings encourage a reevaluation of methyltransferase enzymes’ roles across hematological and solid tumors. Given MYC’s ubiquitous involvement in many cancers, targeting METTL13 or similar modifiers could herald new therapeutic directions with wide applicability. Additionally, the ability to disrupt cancer cell survival pathways at the translational level represents a paradigm shift, signifying an era where cancer treatment is informed by multilayered regulatory networks rather than single-gene targets.

In the clinical context, integrating METTL13 expression levels into diagnostic and prognostic workflows could refine patient stratification and guide personalized treatment decisions. Patients with elevated METTL13 might benefit from tailored therapies that specifically disrupt the METTL13-MYC axis. Moreover, monitoring METTL13 activity longitudinally could serve as an indicator of treatment response and disease progression, aiding clinicians in optimizing management strategies.

The discovery also emphasizes the importance of interdisciplinary research, combining molecular biology, biochemistry, genomics, and clinical sciences to unravel complex oncogenic pathways. The collaborative approach enabled a comprehensive characterization of METTL13’s function from molecular mechanisms to clinical implications, serving as a model for future translational cancer research endeavors.

Looking ahead, the field is poised for exciting developments as efforts focus on designing and testing METTL13 inhibitors in preclinical models and eventually clinical trials. Success in these steps could revolutionize AML therapy, offering hope for improved survival and quality of life for patients afflicted by this aggressive leukemia. The ongoing work will also likely stimulate broader investigations into epigenetic regulation mechanisms underpinning cancer, potentially unveiling new classes of druggable targets.

In conclusion, the revelation that METTL13 is indispensable for AML cell survival by modulating MYC expression not only enriches the understanding of leukemia biology but also spotlights a promising therapeutic target with far-reaching implications. By bridging epitranscriptomics and oncogenic signaling, this study paves the way for innovative cancer treatments that disrupt fundamental pathological processes. As research progresses, targeting METTL13 may emerge as a game-changer in the fight against AML and beyond, offering renewed optimism in conquering one of the deadliest forms of cancer.

Subject of Research: The role of METTL13 in the survival of acute myeloid leukemia cells through regulation of MYC.

Article Title: METTL13 is essential for the survival of acute myeloid leukemia cells by regulating MYC.

Article References:
Zhao, K., Zhang, H., Wang, S. et al. METTL13 is essential for the survival of acute myeloid leukemia cells by regulating MYC. Cell Death Discov. 11, 240 (2025). https://doi.org/10.1038/s41420-025-02512-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02512-x